PTGX (Protagonist Therapeutics) Cyclically Adjusted Revenue per Share: $2.05 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PTGX Protagonist Therapeutics Inc PTGX
47 GF Score
Price $135.43
GF Value $67.13
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Protagonist Therapeutics Cyclically Adjusted Revenue per Share?

Protagonist Therapeutics PTGX -0.01% 47 Cyclically Adjusted Revenue per Share is $2.05 as of Mar. 2026. GuruFocus rates PTGX with a GF Score™ of 47/100 and a GF Value™ of $67.13 (Significantly Overvalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Protagonist Therapeutics's adjusted revenue per share for the three months ended in Mar. 2026 was $0.800. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $2.05 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Protagonist Therapeutics's average Cyclically Adjusted Revenue Growth Rate was -3.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-24), Protagonist Therapeutics's current stock price is $135.43. Protagonist Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $2.05. Protagonist Therapeutics's Cyclically Adjusted PS Ratio of today is 66.06.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Protagonist Therapeutics was 68.74. The lowest was 17.35. And the median was 28.30.


Protagonist Therapeutics  (NAS:PTGX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Protagonist Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=135.43/2.05
=66.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Protagonist Therapeutics was 68.74. The lowest was 17.35. And the median was 28.30.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Protagonist Therapeutics Cyclically Adjusted Revenue per Share Related Terms


Protagonist Therapeutics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Protagonist Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Protagonist Therapeutics Cyclically Adjusted Revenue per Share Chart

Protagonist Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 2.11 1.97

Protagonist Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.13 2.08 2.03 1.97 2.05

PTGX vs IMVT, SYRE, MIRM: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Protagonist Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Protagonist Therapeutics Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protagonist Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Protagonist Therapeutics's Cyclically Adjusted PS Ratio falls into.


PTGX
47GF Score
Protagonist Therapeutics Inc PTGX
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Protagonist Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Protagonist Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.8/330.2130*330.2130
=0.800

Current CPI (Mar. 2026) = 330.2130.

Protagonist Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.000 241.018 0.000
201609 0.000 241.428 0.000
201612 0.000 241.432 0.000
201703 0.000 243.801 0.000
201706 0.000 244.955 0.000
201709 0.519 246.819 0.694
201712 0.558 246.524 0.747
201803 0.511 249.554 0.676
201806 0.550 251.989 0.721
201809 0.267 252.439 0.349
201812 0.097 251.233 0.127
201903 0.064 254.202 0.083
201906 -0.332 256.143 -0.428
201909 0.154 256.759 0.198
201912 0.098 256.974 0.126
202003 0.132 258.115 0.169
202006 0.190 257.797 0.243
202009 0.351 260.280 0.445
202012 0.143 260.474 0.181
202103 0.140 264.877 0.175
202106 0.050 271.696 0.061
202109 0.214 274.310 0.258
202112 0.179 278.802 0.212
202203 0.528 287.504 0.606
202206 0.018 296.311 0.020
202209 0.000 296.808 0.000
202212 0.000 296.797 0.000
202303 0.000 301.836 0.000
202306 0.000 305.109 0.000
202309 0.000 307.789 0.000
202312 0.993 306.746 1.069
202403 4.009 312.332 4.239
202406 0.068 314.175 0.071
202409 0.076 315.301 0.080
202412 2.567 315.605 2.686
202503 0.450 319.799 0.465
202506 0.087 322.561 0.089
202509 0.074 324.800 0.075
202512 0.116 324.054 0.118
202603 0.800 330.213 0.800

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $2.05 mean?
Protagonist Therapeutics (PTGX) has a Cyclically Adjusted Revenue per Share of $2.05 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Protagonist Therapeutics and its competitors.
Is Protagonist Therapeutics' Cyclically Adjusted Revenue per Share too high?
Protagonist Therapeutics' current Cyclically Adjusted Revenue per Share is $2.05. Overall, Protagonist Therapeutics has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Protagonist Therapeutics' Cyclically Adjusted Revenue per Share compare to IMVT and SYRE?
Protagonist Therapeutics' Cyclically Adjusted Revenue per Share of $2.05 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Protagonist Therapeutics and its competitors. Protagonist Therapeutics's current Cyclically Adjusted Revenue per Share is $2.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protagonist Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Protagonist Therapeutics (PTGX) is currently considered Significantly Overvalued. The stock's GF Value™ is $67.13, compared to a current price of $135.43 — trading 101.7% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $2.05. Protagonist Therapeutics' overall GF Score™ is 47/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Protagonist Therapeutics (PTGX), the current Cyclically Adjusted Revenue per Share is $2.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Protagonist Therapeutics (PTGX) Overvalued in 2026?

Based on GuruFocus' analysis, Protagonist Therapeutics stock appears to be overvalued. The current stock price of $135.43 is trading 101.7% above its estimated GF Value™ of $67.13. GuruFocus considers Protagonist Therapeutics to be Significantly Overvalued.

Key valuation signals for PTGX:

  • Cyclically Adjusted Revenue per Share: $2.05
  • GF Value™: $67.13 vs. price of $135.43 (101.7% above fair value)
  • GF Score™: 47/100 with 8 warning signs

No single metric tells the full story. See the PTGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Protagonist Therapeutics Business Description

Address 7707 Gateway Boulevard, Suite 140, Newark, CA, USA, 94560
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
47GF Score

Get the complete analysis for PTGX

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$135.43
Price
$67.13
GF Value